Investigation of IsoRay, Inc. Announced by Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of IsoRay, Inc. (“IsoRay” or the “Company”) (NYSE: ISR) concerning recent reports that the Company has manipulated the presentation of its clinical data to mislead investors regarding the clinical success of its cancer treatments. Glancy Prongay & Murray LLP is preparing a complaint to recover losses sustained by investors in the wake of recent disclosures regarding IsoRay’s misleading statements.

On May 21, 2015, thestreet.com published a report entitled, “IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price.” The report stated that, “IsoRay (ISR - Get Report) does a poor job selling radioactive 'seeds' for use in cancer radiation therapy. To make up for the inability to deliver revenue growth -- and prop up its stock price -- IsoRay issues a lot of promotional press releases, some of which take liberties with clinical data using clever, selective editing.” The report continues, “IsoRay also plays rope-a-dope with the five-year overall survival rate of 100% for Cesium-131 patients. The company fails to mention the comparable five-year survival rate for patients undergoing surgery alone is 98% -- a clinically meaningless difference of two percentage points. Moreover, the survival analysis is severely limited because nearly every patient in the study is censored, meaning they're lost to follow up. The study does not conclude that treatment with Cesium-131 leads to longer survival.”

On this news, shares of IsoRay fell $1.10 per share, or 35%, to close on May 21, 2015 at $2.02 per share.

If you purchased IsoRay shares or other securities prior to May 21, 2015, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150522005631/en/